The Influence of Antipsychotics on the Quality of Life of Patients with Schizophrenia in a Long-stay Psychiatric Facility

1. Chan GW, Ungvari GS, Shek DT, Leung Dagger JJ.Hospital and community-based care for patients with chronic schizophrenia in Hong Kong- quality of life and its correlates. Soc Psychiatry Psychiatr Epidemiol 2003; 38(4): 196-203.10.1007/s00127-003-0616-512664230Search in Google Scholar

2. Salome F, Petitjean F, Germain C, Demant JC. The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients’ expectations.Search in Google Scholar

A comparative study. Encephale 2004; 30(1): 60-8.10.1080/00963402.2004.11460817Search in Google Scholar

3. Rossler W, Salize HJ, Cucchiaro G, Reinhard I, Kernig C.Does the place of treatment influence the quality of life of schizophrenics? Acta Psychiatr Scand. 1999; 100(2): 142-8.10.1111/j.1600-0447.1999.tb10835.x10480200Search in Google Scholar

4. Nuss P, Tessier C. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride. Curr Med Res Opin. 2010; 26(4): 787-801.10.1185/0300799090357695320121655Search in Google Scholar

5. Kane JM, Kim E, Kan HJ, Guo Z, Bates JA, Whitehead R, Pikalov A. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy. 2009; 7(2): 109-19.10.1007/BF0325614519731968Search in Google Scholar

6. Bebbington PE, Angermeyer M, Azorin JM, Marwaha S, Marteau F, Toumi M. Side-effects of antipsychotic medication and health-related quality of life in schizophrenia.Acta Psychiatr Scand Suppl. 2009; 438: 22-8.10.1111/j.1600-0447.2008.01310.x19132963Search in Google Scholar

7. www.who.intSearch in Google Scholar

8. Mas-Exposito L, Amador-Campos JA, Gomez-Benito J, Lalucat-Jo L. The World Health Organization Quality of Life Scale Brief Version: a validation study in patients with schizophrenia. Qual Life Res. 2011; 20(7): 1079-89.10.1007/s11136-011-9847-121290191Search in Google Scholar

9. World Health Organization. ICD-10 Chapter V. Diagnostic Criteria for Research. Genova: WHO, 1993.Search in Google Scholar

10. Zaghdoudi L, Homri W, Belaid S, Ben Bechir M, Labbane R. Quality of life of patient with schizophrenia treated by conventional and atypical neuroleptics. Tunis Med. 2009; 87(9): 593-8.Search in Google Scholar

11. Zhang PL, Santos JM, Newcomer J, Pelfrey BA, Johnson MC. Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients. Schizophr Res. 2004; 71(1): 137-44. 10.1016/j.schres.2003.11.00515374581Search in Google Scholar

12. Midori Fujikawa, Takashi Togo, Asuka Yoshimi et al Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients. Progress in Neuro Psychopharmacology & Biological Psychiatry 2008; 32: 755-760.10.1016/j.pnpbp.2007.12.00218226436Search in Google Scholar

13. Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54: 719-23.10.1176/appi.ps.54.5.71912719504Search in Google Scholar

14. Lambert M, Schimmelmann BG, Naber D, Schacht A, Karow A,Wagner T, et al Prediction of remission as a combination of symptomatic and functionalremission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 2006; 67: 1690-7.10.4088/JCP.v67n110417196047Search in Google Scholar

15. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents. Am J Psychiatry 2002; 159: 103-8.10.1176/appi.ajp.159.1.10311772697Search in Google Scholar

16. Ritchie CW, Chiu E, Harrigan S, Hall K, Hassett A, Macfarlane S et al The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. Int J Geriatr Psichiatry 2003; 18(5): 432-40.10.1002/gps.86212766921Search in Google Scholar

17. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al Randomized controlled trial of the effect on quality of life of second- vs firstgeneration antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUt- LASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.10.1001/archpsyc.63.10.107917015810Search in Google Scholar

18. Loffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients’ subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36: 105-12.10.1055/s-2003-3998512806568Search in Google Scholar

19. Diaz E, Neuse E, Sullivan MC, Pearsall HR, Woods SW.Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65: 354-60. 10.4088/JCP.v65n0311Search in Google Scholar